Glycostem and Ghent University sign license agreement on NK cell therapy technology

17th December, 2020 – Glycostem Therapeutics and Ghent University (UGent) have signed a license agreement for an innovative NK cell production technology. Ultimately, this agreement will bring significant benefit to targeted treatment of patients suffering from cancer.

Glycostem announces treatment of first patient in pivotal phase I/IIa trial

15th December, 2020 – Glycostem today announced that the first patient has been dosed in its pivotal phase I/IIa trial of oNKord® for the treatment of Acute Myeloid Leukemia (AML). The WiNK trial will enroll 33 AML patients at eight clinical sites based in five European countries.

Glycostem initiates phase I/IIa trial of oNKord® in patients with Acute Myeloid Leukemia

20th November 2020 – Glycostem today announced the opening of a phase I/IIa trial for its lead product oNKord® for the treatment of AML patients. The WiNK trial will enroll 33 AML patients at eight clinical sites based in five European countries.

FDA grants Glycostem’s oNKord® Orphan Drug Designation for Multiple Myeloma

12th October 2020 - Glycostem announces it has received the FDA’s Orphan Drug Designation (ODD) for treatment of Multiple Myeloma (MM) patients with its investigational product oNKord®.

Glycostem collaborates with LUMICKS

30th July, 2020 - Glycostem collaborates with LUMICKS to improve immunotherapeutic drug development. By quantifying binding strength between immune and cancer cells using the unique z-Movi® Cell Avidity Analyzer, Glycostem exploits the predictiveness of avidity in finding the best NK-cell population for cellular therapy.

Glycostem partners with Zelluna Immunotherapy

19th November, 2019 - Zelluna Immunotherapy, a biopharma company developing T-cell receptor (TCR) guided adoptive cell therapy products for the treatment  of  multiple  solid  cancers, and Glycostem Therapeutics BV,  a  clinical  stage  and leading Natural Killer (NK) cell manufacturing company, today announce that they have entered  into  a  de

Glycostem welcomes Dr Rizwan Romee as US based advisor

12th September 2019 - Glycostem Therapeutics BV, a clinical stage and leading NK cell company,today announced to have welcomed Rizwan

Glycostem signs first commercial agreement for oNKord® and new CAR-NK co-development agreement

11th September 2019 - Glycostem Therapeutics BV, a clinical stage and leading NK cell company, today announced the signing of a two agreements with an undisclo

Glycostem successfully completes funding round

9th September 2019 - Glycostem Therapeutics BV, a clinical stage and leading NK-cell company today announced that Korean investor, E&F Healthcare Holdings and existing investor LUPUS Ventures B.V